Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Net Loss Per Share

Note 15 - Net Loss Per Share

9 Months Ended

Sep. 30, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

15. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

	*Three Months Ended*						*Nine Months Ended*
	*September 30,*						*September 30,*
	*2024*			*2023*			*2024*			*2023*
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(2,072	)	$	(3,365	)	$	(7,917	)	$	(11,984	)

Denominator:
Weighted-average number of common shares, basic and diluted		20,310			14,073			18,657			13,672

Net loss per common share, basic and diluted	$	(0.10	)	$	(0.24	)	$	(0.42	)	$	(0.88	)

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive as of the end of each period presented:

	*Three Months Ended*				*Nine Months Ended*
	*September 30,*				*September 30,*
	*2024*		*2023*		*2024*		*2023*
Options to purchase common stock		185		254		185		254
Restricted stock units		1,034		1,474		1,034		1,474
Warrants for common stock⁽¹⁾		13,047		1,240		13,047		1,240
Total common stock equivalents		14,266		2,968		14,266		2,968

⁽¹⁾ Represents the number of shares of common stock underlying our outstanding warrants as of such dates except for the 2,900 shares of common stock underlying the Pre-Funded Warrant issued during the three and nine months ended September 30, 2024. Refer to Note 11. Capitalization and Equity Structure – Warrants for additional information regarding the warrants.